VC
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Fisher | Fisher Asset Management | $41M | 0.0% | 2026-06-30 |
| Ray Dalio | Bridgewater Associates | $3M | 0.0% | 2026-06-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Methodology breakdown computing — it will appear here on its own.
Veracyte Inc (VCYT) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-06). See the full ratio breakdown and business-activity screen below for the reasoning.
Computing the full ratio and business-activity breakdown for VCYT — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 40.70 | NEUTRAL |
| Stochastic %K (14) | 20.32 | NEUTRAL |
| CCI (20) | -29.60 | NEUTRAL |
| Williams %R (14) | -79.68 | NEUTRAL |
| MACD (12,26,9) | 0.33 | BUY |
| ROC (10) | -5.10 | SELL |
| Momentum (10) | -2.26 | SELL |
| EMA (10) | 43.26 | SELL |
| SMA (10) | 43.56 | SELL |
| EMA (20) | 44.14 | SELL |
| SMA (20) | 42.92 | SELL |
| EMA (30) | 45.28 | SELL |
| SMA (30) | 44.42 | SELL |
| EMA (50) | 46.52 | SELL |
| SMA (50) | 49.69 | SELL |
| EMA (100) | 45.95 | SELL |
| SMA (100) | 46.92 | SELL |
| EMA (200) | 43.10 | SELL |
| SMA (200) | 42.69 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Diagnostics & Research
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Background via Yahoo Finance — informational, not part of the verdict.
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 2 bullish / 1 bearish
Weak — low conviction, small size or skip
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | RANGING | 62 |
| ⏰ 4H | RANGING | 38 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
